The most diffused currently in use are tyrosin kinase inhibitors for EGFR-mutated lung adenocarcinomas, trastuzumab for HER2-negative breast cancer and cetuximab or panituximab for KRAS-mutated CRC (19). Here, KRAS is linked to breast carcinoma.